Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia
Expert Review of Pharmacoeconomics & Outcomes Research · 03.07.2023 · 23 (6) · 691-699
DOI: 10.1080/14737167.2023.2211270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 15.05.2023. Verfasst von N T Connell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: von Willebrand Diseases, Angiodysplasia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A., Inc.
Abstract (Originalsprache)
OBJECTIVE: To describe the economic burden among VWD patients with angiodysplasia compared to VWD patients without angiodysplasia and the general population. METHODS: This was a retrospective analysis using the Merative MarketScan Commercial and Medicare Databases® (January 2011-September 2020). Selected patients had ≥1 medical claim for VWD or low VWF, ≥1 medical claim for AGD, and ≥3 GI-related bleeding episodes within a year. HCRU and all-cause costs were compared with the VWD (only) and the general cohorts. RESULTS: The mean total all-cause costs were $150,101 among patients with VWD and angiodysplasia (n = 34), higher compared to $48,249 among matched VWD patients without angiodysplasia (n = 136) and $31,029 among matched individuals of the general population [n = 136; p-value < 0.0001]. The differences in costs between groups were primarily due to inpatient care. During the 12-month follow-up, VWD patients with symptomatic (n = 35), asymptomatic (n = 81), and suspected (n = 378) angiodysplasia had an average of 4.1, 0.6, and 3.8 gastrointestinal (GI) bleeds, respectively. Desmopressin, VWF concentrates, and aminocaproic acid were the most frequent treatments used. The most frequent procedures to treat GI-related bleeding and underlying lesions were blood transfusion and laser therapy. CONCLUSIONS: Despite recent therapeutic advances, there is room for considerable reduction of the disease burden in patients with VWD and angiodysplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA.
- Complete HEOR Solutions, North Wales, PA, USA.
ORCID-Profile: N T Connell, J Caicedo, S Chatterjee, M Bullano, B G Schultz
Förderung
- Takeda Pharmaceuticals U.S.A., Inc
Zitieren
APA
Connell, N. T., Caicedo, J., Nieto, N., Chatterjee, S., Hait, A., Gupta, A. K., Bullano, M., & Schultz, B. G. (2023). Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia. Expert Review of Pharmacoeconomics & Outcomes Research, 23(6), 691-699. https://doi.org/10.1080/14737167.2023.2211270
Vancouver
Connell NT, Caicedo J, Nieto N, Chatterjee S, Hait A, Gupta AK, et al. Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia. Expert Review of Pharmacoeconomics & Outcomes Research. 2023;23(6):691-699. doi:10.1080/14737167.2023.2211270
BibTeX
@article{Connell2023,
author = {Connell, N T and Caicedo, J and Nieto, N and Chatterjee, S and Hait, A and Gupta, A K and Bullano, M and Schultz, B G},
title = {Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2023},
volume = {23},
number = {6},
pages = {691--699},
doi = {10.1080/14737167.2023.2211270}
}
EUVIMED